Skip Navigation


JAC Advance Access originally published online on April 11, 2005
Journal of Antimicrobial Chemotherapy 2005 55(6):1024-1028; doi:10.1093/jac/dki107
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/1024    most recent
dki107v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Snydman, D. R.
Right arrow Articles by McDermott, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snydman, D. R.
Right arrow Articles by McDermott, L. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group

David R. Snydman1,2,*, Nilda V. Jacobus1 and Laura A. McDermott1

1 Tufts-New England Medical Center, Boston, MA 02111; 2 Tufts University School of Medicine, Boston, MA 02111, USA

* Corresponding author. Tel: +1-617-636-5785; Fax: +1-617-636-8525; Email: dsnydman{at}tufts-nemc.org

Objectives: To compare the in vitro activity of NVP-LMB415 (formerly referred to as NVP-PDF 713) with that of other agents with anti-anaerobe activity against clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Methods: The MICs for 405 B. fragilis group and 102 Gram-positive anaerobic isolates were determined using NCCLS-recommended procedures. The activity of NVP-LMB415 was compared with that of cefoxitin, clindamycin, imipenem, garenoxacin, linezolid, moxifloxacin and tigecycline. Vancomycin was included in the evaluation of the Gram-positive organisms.

Results: NVP-LMB415 showed excellent in vitro activity against all the species of the B. fragilis group isolates (MIC range ≤ 0.03–0.5 mg/L and MIC90 0.5 mg/L). NVP-LMB415 was active against B. fragilis group strains resistant to ß-lactams, quinolones or clindamycin, and the MICs were much lower than those of newer agents such as linezolid, tigecycline and garenoxacin. The MICs of NVP-LMB415 ( ≥ 4 mg/L) for Clostridium species were higher than the MICs for other anaerobes.

Conclusions: Given the frequency of isolation of anaerobic bacteria and their increasing resistance to all classes of antibiotics, NVP-LMB415 is an ideal agent for potential use against mixed infections caused by resistant anaerobic pathogens such as of B. fragilis and Gram-positive aerobic strains such as methicillin-resistant staphylococci, streptococci and enterococci.

Keywords: novel peptide deformylase inhibitor , peptide deformylase inhibitor (PDF) , bacterial metalloproteases , anaerobic pathogens


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
H. M. Wexler
Bacteroides: the Good, the Bad, and the Nitty-Gritty
Clin. Microbiol. Rev., October 1, 2007; 20(4): 593 - 621.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. M Slover, K. A Rodvold, and L. H Danziger
Tigecycline: A Novel Broad-Spectrum Antimicrobial
Ann. Pharmacother., June 1, 2007; 41(6): 965 - 972.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.